XEME Biopharma, Inc.

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

• SMSunil MetkarExecutive Officer
• DNDorel NasuiDirector
• MPMircea PopescuDirector · Executive Officer
• RRRichard RobbExecutive Officer
• ATAnthony TateExecutive Officer
• MTMarius TeodorescuDirector

• 26 Sept 2023Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Deliver Systemgranted
• 20 Feb 2020Cancer Therapy Using A Vaccine In Combination With A Cell-based Immunotherapeutic Agentapplication
• 10 Aug 2017Cancer Therapy Using a Vaccine in Combination with a Cell-Based Immunotherapeutic Agentapplication
• 10 Aug 2017Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery Systemapplication

• 07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
• 30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
• 30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
• 29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
• 26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
• 26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.